go-v.orgdoi

Rilpivirine in the treatment of HIV infection: evidence from the ECHO and THRIVE studies

Pedro Enrique Cahn · Clinical Investigation · 2012

  • DOI 10.4155/cli.12.115
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2012

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2012

Abstract

Rilpivirine (RPV) is a once-daily (qd) non-nucleoside reverse transcriptase inhibitor that was evaluated in antiretroviral treatment-naive, HIV-1-infected adults (with two nucleotide reverse transcriptase inhibitors) in two international, double-blind, double-dummy, Phase III trials (ECHO and THRIVE). Both trials met their primary objective of demonstrating noninferior efficacy of RPV 25-mg qd versus efavirenz 600-mg qd regarding the proportion of patients with a confirmed response (viral load <50 copies/ml, intention-to-treat time-to-loss-of-virologic-response) at week 48. Pooled trial responses were 84 versus 82%, respectively.

While RPV was associated with more virologic failures overall (9 vs 5%) and conveyed a greater risk of resistance-associated mutations developing, in patients with baseline viral load ≤100,000 copies/ml, virologic failures rates were similar (4 vs 3%). RPV was associated with fewer discontinuations due to adverse events (2 vs 7%) and a better tolerability profile, particularly re...

Open the resolved locator · 10.4155/cli.12.115

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:40 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.12.115
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.